A little blurb in today's Xconomy ..... a Seattle business news outlet
Omeros (NASDAQ: OMER): The Seattle company has a whole lot of things going on under one roof, especially for a small biotech worth less than $150 million. There are anti-inflammatory combo drugs for surgeons, targeted antibodies, a G-protein coupled receptor target discovery program, and phosphodiesterase (PDE)-directed small molecule programs for neurological disorders.
Those programs are at various stages in the R&D continuum, and most of them are still early. But Omeros does have a news hook coming, as CEO Greg Demopulos said the company plans to file formal paperwork to seek FDA approval of OMS302 “in the coming weeks.” That’s the two-drug combo that matches an anti-inflammatory with a pupil-dilating agent to assist doctors during surgery to fix cataracts, or do what’s called a refractive lens exchange. If the drug passes muster with the FDA, it will be Omeros’ first product cleared for sale, and will provide revenue it can plow into its portfolio of other product candidates. Demopulos said he envisions building “a pipeline in perpetuity for Omeros.”